News

In April 2013, Valeant offered Actavis the rights to Metronidazole 1.3%, which provides a convenient, single-dose treatment for BV. BV is an infection caused by an imbalance in

The products include prescription drugs to treat patients undergoing ocular interventions or suffering from infections or inflammatory diseases of the eye. In particular, the portfolio includes two artificial

This method of use patent covers the company’s Brisdelle (paroxetine) capsules, 7.5mg, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to

The 28-month contract, a follow-on option to a contract begun in 2011, will include development of additional clinical supplies, regulatory filings and testing in two animal models to

Zorvolex was approved in October 2013 by the US Food and Drug Administration (FDA) for the treatment of mild to moderate acute pain in adults. Iroko president and

The most recent order for TapouT-branded products was for Go4ITNutrition.com. Go4ITNutrition is an online marketplace that deals specifically in sports supplements and sports nutrition products. The website features

Earlier in March 2013, the company had submitted the marketing authorization application (MAA) to the TGA for review of Latuda. Lurasidone is an atypical antipsychotic agent, developed by

Around 16 chronic HBV patients will be enrolled in multi-center, randomized, double-blind, placebo-controlled, dose-escalation Phase IIa trial, which is being conducted at Queen Mary Hospital and Prince of

According to the company, the new product is shipped as a flow-through and will be available at all existing retailers, including major drugstores CVS, Walgreens and Rite-Aid, mass